Efficacy of intracoronary abciximab in percutaneous coronary intervention

Comparison of cardiovascular outcomes (repeated infarction, infarct size, hemorrhage, and death) of intracoronary abciximab or intravenous eptifibatide administration during percutaneous coronary intervention of ST-segment elevation myocardial infarction

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012081310573N1

Enrollment

Registered

2012-09-09

Start date

2011-08-27

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ST-segment elevation myocardial infarction. myocardial infarction specified as acute or with a stated duration of 4 weeks (28 days) or less from onset

Interventions

Intervention 1: In control group, two boluses of eptifibatide (each 180 microgram per kilogram body weight) were administered intravenously 10 minutes apart during percutaneous coronary intervention.

Treatment - Drugs

In control group, two boluses of eptifibatide (each 180 microgram per kilogram body weight) were administered intravenously 10 minutes apart during percutaneous coronary intervention.

In intervention group, abciximab with a dosage of 0.25 microgram per kilogram body weight was administered into coronary arteries via microcatheter during percutaneous coronary intervention.

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: ST elevation myocardial infarction (MI) Exclusion criteria: patients presenting with ST-elevation myocardial infarction after 12 hours from symptoms onset; patients presenting with vasospastic angina (determined by resolution of ST segment elevation, and relief of symptoms after intravenous administration of nitroglycerin); patients presenting with non-ST elevation MI; contraindications for antiplatelets such as bleeding disorder including gastrointestinal bleeding, hematuria, or any known bleeding tendency either inherited or acquired; thrombocytopenia (Platelet count less than 100.000 per microliter; recent (less than 6 months) stroke; intracranial hemorrhage at any time in patient's life or any known intracranial malformation; cardiogenic shock; left bundle branch block changes on ECG.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Infarct size. Timepoint: Day 2. Method of measurement: Area under the curve of the cardiac creatine kinase-MB release.;Myocardial reperfusion. Timepoint: First day. Method of measurement: resolution of ST segment elevation.;Reinfarction. Timepoint: Days 1 to 7. Method of measurement: Recurrent symptoms suggestive of ischemia with new ST-segment elevation and/or elevation of serum cardiac markers levels.	—

Measure

Time frame

Infarct size. Timepoint: Day 2. Method of measurement: Area under the curve of the cardiac creatine kinase-MB release.;Myocardial reperfusion. Timepoint: First day. Method of measurement: resolution of ST segment elevation.;Reinfarction. Timepoint: Days 1 to 7. Method of measurement: Recurrent symptoms suggestive of ischemia with new ST-segment elevation and/or elevation of serum cardiac markers levels.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Hassan Namazi

Shahid Beheshti Cardiovascular Research Center

namazimh@gmail.com+98 21 2208 3106

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026